Free Trial

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Squarepoint Ops LLC

Amicus Therapeutics logo with Medical background

Squarepoint Ops LLC lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 113.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,417,152 shares of the biopharmaceutical company's stock after purchasing an additional 753,060 shares during the period. Squarepoint Ops LLC owned about 0.47% of Amicus Therapeutics worth $13,350,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in FOLD. Covestor Ltd boosted its stake in shares of Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after buying an additional 2,312 shares during the period. R Squared Ltd acquired a new stake in Amicus Therapeutics during the 4th quarter worth approximately $79,000. KBC Group NV grew its stake in shares of Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after purchasing an additional 3,120 shares during the last quarter. Sciencast Management LP acquired a new stake in shares of Amicus Therapeutics in the 4th quarter worth $100,000. Finally, Stephens Inc. AR acquired a new stake in shares of Amicus Therapeutics in the 4th quarter worth $101,000.

Amicus Therapeutics Price Performance

Shares of FOLD stock traded up $0.04 during mid-day trading on Tuesday, reaching $6.26. The stock had a trading volume of 2,591,927 shares, compared to its average volume of 3,350,180. The company has a market cap of $1.93 billion, a P/E ratio of -34.72, a price-to-earnings-growth ratio of 1.51 and a beta of 0.64. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 12-month low of $5.81 and a 12-month high of $12.65. The business has a 50-day simple moving average of $7.05 and a 200 day simple moving average of $8.68.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. The Goldman Sachs Group reduced their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. UBS Group increased their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Wall Street Zen downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Finally, Wells Fargo & Company reduced their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $16.22.

Get Our Latest Stock Analysis on FOLD

Amicus Therapeutics Profile

(Free Report)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Further Reading

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Should You Invest $1,000 in Amicus Therapeutics Right Now?

Before you consider Amicus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.

While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines